Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 4
1991 12
1992 7
1993 22
1994 7
1995 15
1996 42
1997 13
1998 34
1999 35
2000 35
2001 30
2002 36
2003 44
2004 30
2005 47
2006 32
2007 52
2008 36
2009 33
2010 36
2011 40
2012 63
2013 50
2014 52
2015 55
2016 37
2017 46
2018 51
2019 73
2020 85
2021 98
2022 36
Text availability
Article attribute
Article type
Publication date

Search Results

1,192 results
Results by year
Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, Damiani LP, Marcadenti A, Kawano-Dourado L, Lisboa T, Junqueira DLM, de Barros E Silva PGM, Tramujas L, Abreu-Silva EO, Laranjeira LN, Soares AT, Echenique LS, Pereira AJ, Freitas FGR, Gebara OCE, Dantas VCS, Furtado RHM, Milan EP, Golin NA, Cardoso FF, Maia IS, Hoffmann Filho CR, Kormann APM, Amazonas RB, Bocchi de Oliveira MF, Serpa-Neto A, Falavigna M, Lopes RD, Machado FR, Berwanger O; Coalition Covid-19 Brazil I Investigators. Cavalcanti AB, et al. N Engl J Med. 2020 Nov 19;383(21):2041-2052. doi: 10.1056/NEJMoa2019014. Epub 2020 Jul 23. N Engl J Med. 2020. PMID: 32706953 Free PMC article. Clinical Trial.
BACKGROUND: Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). ...CONCLUSIONS: Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not …
BACKGROUND: Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). ...CONCLUS …
Azithromycin for prevention of exacerbations of COPD.
Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR; COPD Clinical Research Network. Albert RK, et al. N Engl J Med. 2011 Aug 25;365(8):689-98. doi: 10.1056/NEJMoa1104623. N Engl J Med. 2011. PMID: 21864166 Free PMC article. Clinical Trial.
The frequency of exacerbations was 1.48 exacerbations per patient-year in the azithromycin group, as compared with 1.83 per patient-year in the placebo group (P=0.01), and the hazard ratio for having an acute exacerbation of COPD per patient-year in the azithromycin
The frequency of exacerbations was 1.48 exacerbations per patient-year in the azithromycin group, as compared with 1.83 per patient-y …
Azithromycin or Doxycycline for Asymptomatic Rectal Chlamydia trachomatis.
Lau A, Kong FYS, Fairley CK, Templeton DJ, Amin J, Phillips S, Law M, Chen MY, Bradshaw CS, Donovan B, McNulty A, Boyd MA, Timms P, Chow EPF, Regan DG, Khaw C, Lewis DA, Kaldor J, Ratnayake M, Carvalho N, Hocking JS. Lau A, et al. N Engl J Med. 2021 Jun 24;384(25):2418-2427. doi: 10.1056/NEJMoa2031631. N Engl J Med. 2021. PMID: 34161706 Clinical Trial.
RESULTS: From August 2016 through August 2019, we enrolled 625 men (314 in the doxycycline group and 311 in the azithromycin group). Primary outcome data were available for 290 men (92.4%) in the doxycycline group and 297 (95.5%) in the azithromycin group. ...CONCLU …
RESULTS: From August 2016 through August 2019, we enrolled 625 men (314 in the doxycycline group and 311 in the azithromycin group). …
Adjunctive Azithromycin Prophylaxis for Cesarean Delivery.
Tita AT, Szychowski JM, Boggess K, Saade G, Longo S, Clark E, Esplin S, Cleary K, Wapner R, Letson K, Owens M, Abramovici A, Ambalavanan N, Cutter G, Andrews W; C/SOAP Trial Consortium. Tita AT, et al. N Engl J Med. 2016 Sep 29;375(13):1231-41. doi: 10.1056/NEJMoa1602044. N Engl J Med. 2016. PMID: 27682034 Free PMC article. Clinical Trial.
BACKGROUND: The addition of azithromycin to standard regimens for antibiotic prophylaxis before cesarean delivery may further reduce the rate of postoperative infection. We evaluated the benefits and safety of azithromycin-based extended-spectrum prophylaxis in wome …
BACKGROUND: The addition of azithromycin to standard regimens for antibiotic prophylaxis before cesarean delivery may further reduce …
Macrolide and Nonmacrolide Resistance with Mass Azithromycin Distribution.
Doan T, Worden L, Hinterwirth A, Arzika AM, Maliki R, Abdou A, Zhong L, Chen C, Cook C, Lebas E, O'Brien KS, Oldenburg CE, Chow ED, Porco TC, Lipsitch M, Keenan JD, Lietman TM. Doan T, et al. N Engl J Med. 2020 Nov 12;383(20):1941-1950. doi: 10.1056/NEJMoa2002606. N Engl J Med. 2020. PMID: 33176084 Free PMC article. Clinical Trial.
The effects on the gut resistome, a reservoir of antimicrobial resistance genes in the body, of twice-yearly administration of azithromycin for a longer period are unclear. METHODS: We investigated the gut resistome of children after they received twice-yearly distribution …
The effects on the gut resistome, a reservoir of antimicrobial resistance genes in the body, of twice-yearly administration of azithromyc
Randomised trial of azithromycin to eradicate Ureaplasma in preterm infants.
Viscardi RM, Terrin ML, Magder LS, Davis NL, Dulkerian SJ, Waites KB, Ambalavanan N, Kaufman DA, Donohue P, Tuttle DJ, Weitkamp JH, Hassan HE, Eddington ND. Viscardi RM, et al. Arch Dis Child Fetal Neonatal Ed. 2020 Nov;105(6):615-622. doi: 10.1136/archdischild-2019-318122. Epub 2020 Mar 13. Arch Dis Child Fetal Neonatal Ed. 2020. PMID: 32170033 Free PMC article. Clinical Trial.
OBJECTIVE: To test whether azithromycin eradicates Ureaplasma from the respiratory tract in preterm infants. ...Forty-four of 121 participants (36%) were Ureaplasma positive (azithromycin: n=19; placebo: n=25). Ureaplasma-free survival was 55/60 (92% (95% CI 82% to …
OBJECTIVE: To test whether azithromycin eradicates Ureaplasma from the respiratory tract in preterm infants. ...Forty-four of 121 par …
Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial.
Oldenburg CE, Pinsky BA, Brogdon J, Chen C, Ruder K, Zhong L, Nyatigo F, Cook CA, Hinterwirth A, Lebas E, Redd T, Porco TC, Lietman TM, Arnold BF, Doan T. Oldenburg CE, et al. JAMA. 2021 Aug 10;326(6):490-498. doi: 10.1001/jama.2021.11517. JAMA. 2021. PMID: 34269813 Free PMC article. Clinical Trial.
IMPORTANCE: Azithromycin has been hypothesized to have activity against SARS-CoV-2. ...DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial of azithromycin vs matching placebo conducted from May 2020 through March 2021. ...
IMPORTANCE: Azithromycin has been hypothesized to have activity against SARS-CoV-2. ...DESIGN, SETTING, AND PARTICIPANTS: Randomized …
Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.
Izadi M, Dadsetan B, Najafi Z, Jafari S, Mazaheri E, Dadras O, Heidari H, SeyedAlinaghi S, Voltarelli F. Izadi M, et al. Recent Pat Antiinfect Drug Discov. 2018;13(3):228-239. doi: 10.2174/1574891X13666181024154526. Recent Pat Antiinfect Drug Discov. 2018. PMID: 30360748 Clinical Trial.
One group was treated with oral Levofloxacin (TAVANEX), 750 mg, once daily for five days and the other group with parenteral Ceftriaxone 1gr BD plus oral Azithromycin (250 mg, once daily) for seven to ten days (standard regimen). ...CONCLUSION: We concluded that monotherap …
One group was treated with oral Levofloxacin (TAVANEX), 750 mg, once daily for five days and the other group with parenteral Ceftriaxone 1gr …
Which azithromycin regimen should be used for treating Mycoplasma genitalium? A meta-analysis.
Horner P, Ingle SM, Garrett F, Blee K, Kong F, Muir P, Moi H. Horner P, et al. Sex Transm Infect. 2018 Feb;94(1):14-20. doi: 10.1136/sextrans-2016-053060. Epub 2017 Jul 17. Sex Transm Infect. 2018. PMID: 28717050 Review.
BACKGROUND: There is increasing evidence that azithromycin 1 g is driving the emergence of macrolide resistance in Mycoplasma genitalium worldwide. We undertook a meta-analysis of M. genitalium treatment studies using azithromycin 1 g single dose and azithromycin
BACKGROUND: There is increasing evidence that azithromycin 1 g is driving the emergence of macrolide resistance in Mycoplasma genital …
Azithromycin versus Doxycycline for Urogenital Chlamydia trachomatis Infection.
Geisler WM, Uniyal A, Lee JY, Lensing SY, Johnson S, Perry RC, Kadrnka CM, Kerndt PR. Geisler WM, et al. N Engl J Med. 2015 Dec 24;373(26):2512-21. doi: 10.1056/NEJMoa1502599. N Engl J Med. 2015. PMID: 26699167 Free PMC article. Clinical Trial.
Recent studies have raised concern about the efficacy of azithromycin for the treatment of chlamydia infection. METHODS: We conducted a randomized trial comparing oral azithromycin with doxycycline for the treatment of urogenital chlamydia infection among adolescent …
Recent studies have raised concern about the efficacy of azithromycin for the treatment of chlamydia infection. METHODS: We conducted …
1,192 results